Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab
Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care...
Saved in:
| Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 28; no. 2; pp. 329 - 332 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.02.2022
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome. |
|---|---|
| AbstractList | Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome. Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome.Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome. |
| Author | Tachikawa, Natsuo Miyazaki, Kazuhito Sasaki, Hiroaki Miyata, Nobuyuki Horiuchi, Hiroshi Yoshimura, Yukihiro |
| Author_xml | – sequence: 1 givenname: Hiroshi orcidid: 0000-0001-9684-4520 surname: Horiuchi fullname: Horiuchi, Hiroshi email: jevousremerciebeaucoup@hotmail.co.jp – sequence: 2 givenname: Hiroaki surname: Sasaki fullname: Sasaki, Hiroaki – sequence: 3 givenname: Kazuhito orcidid: 0000-0002-0079-2883 surname: Miyazaki fullname: Miyazaki, Kazuhito – sequence: 4 givenname: Nobuyuki surname: Miyata fullname: Miyata, Nobuyuki – sequence: 5 givenname: Yukihiro surname: Yoshimura fullname: Yoshimura, Yukihiro – sequence: 6 givenname: Natsuo surname: Tachikawa fullname: Tachikawa, Natsuo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34887178$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1u1DAUhSNURH_gBVggL9kk-Mb5MQghVQOFSpUqtVCxsxz7hvGQxKntDORZ-rI4TIugiyJZ8rV9vnNtn8Nkb7ADJslzoBlQqF5tso2RKstpDhlARoE_Sg6gYHVa15zuxZoVkLIcvu4nh95vKIW65PxJss8Kzmuo-UFyc4HKbtHNpHW2Jx5jjWRE540POASyOr86fZ_Ca_LDhLWdAsGt0TgoJLYlcogjmPTy-OIyXdmrNP-9bqyeiUM_2sEjMVFE-ihdHJYidEgUdh3p5n5c216S4FAG1DuFM2H6aXrZPE0et7Lz-Ox2Pkq-nHz4vPqUnp1_PF0dn6WqZDSkkmospa5KpI1WDDTWquWsaiqmmZYta4u8kCzuVZQi5AxQNq1inLW1LGjOjpJ3O99xanrUKj7byU6MLl7CzcJKI_49GcxafLNbwSvIObBo8PLWwNnrCX0QvfHLC-WAdvIirygvWQ0Vj9IXf_f60-QukSjgO4Fy1nuHrVAmyGDs0tp0AqhYwhcbsYQvlvAFgIjhRzS_h965Pwi93UEYf3hr0AmvzJKvNg5VENqah_E393DVmcEo2X3H-X_wL-O232w |
| CitedBy_id | crossref_primary_10_7759_cureus_48319 crossref_primary_10_2147_IDR_S360238 crossref_primary_10_1007_s40278_022_13837_y crossref_primary_10_1093_ofid_ofad189 crossref_primary_10_1007_s40472_022_00385_y crossref_primary_10_1016_j_jiac_2023_10_022 crossref_primary_10_2169_internalmedicine_0241_22 |
| Cites_doi | 10.1111/bjh.16935 10.3201/eid2701.203772 10.3389/fonc.2020.01578 10.1111/bjh.16896 10.1038/s41408-021-00546-9 10.1186/s13027-021-00376-1 10.1016/j.clml.2020.06.012 10.1016/S2352-3026(20)30251-9 10.1093/infdis/jiaa666 10.1056/NEJMoa2034577 10.1016/j.transci.2020.102871 |
| ContentType | Journal Article |
| Copyright | 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
| Copyright_xml | – notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases – notice: Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. – notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.jiac.2021.11.018 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1437-7780 |
| EndPage | 332 |
| ExternalDocumentID | PMC8612813 34887178 10_1016_j_jiac_2021_11_018 S1341321X21003299 |
| Genre | Journal Article |
| GroupedDBID | --- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO AAYZH ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGCQF AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF AACTN AAIAV ABLVK ABTEG ABYKQ ADINQ AFKWA AFNRJ AHPSJ AJBFU AJOXV AMFUW EFLBG GQ6 NCXOZ RIG SSI SZN Z7U Z82 Z87 Z8O Z8V Z91 AAYXX AFCTW AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c530t-a0de5ad65e0bdc31de7cf836b63d3daf3f424a3cf8600e1231eabfc383f7a4023 |
| IEDL.DBID | .~1 |
| ISSN | 1341-321X 1437-7780 |
| IngestDate | Thu Aug 21 14:10:46 EDT 2025 Fri Jul 11 07:25:41 EDT 2025 Wed Feb 19 02:28:12 EST 2025 Tue Jul 01 02:23:37 EDT 2025 Thu Apr 24 23:05:42 EDT 2025 Fri Feb 23 02:40:33 EST 2024 Tue Aug 26 18:42:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | COVID-19 Rituximab SARS-CoV-2 Antibody Lymphoma Immunocompromised state |
| Language | English |
| License | Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c530t-a0de5ad65e0bdc31de7cf836b63d3daf3f424a3cf8600e1231eabfc383f7a4023 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0079-2883 0000-0001-9684-4520 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8612813 |
| PMID | 34887178 |
| PQID | 2608537168 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8612813 proquest_miscellaneous_2608537168 pubmed_primary_34887178 crossref_citationtrail_10_1016_j_jiac_2021_11_018 crossref_primary_10_1016_j_jiac_2021_11_018 elsevier_sciencedirect_doi_10_1016_j_jiac_2021_11_018 elsevier_clinicalkey_doi_10_1016_j_jiac_2021_11_018 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| PublicationTitleAlternate | J Infect Chemother |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
| References | Passamonti, Cattaneo, Arcaini (bib12) 2020 Oct; 7 Shah, Ko Ko, Zuckerman (bib5) 2020 Sep; 190 Schwarzkopf, Krawczyk, Knop (bib11) 2021 Jan; 27 Kim, Lee, Kim (bib1) 2020 Nov; 24 Marasco, Carniti, Guidetti (bib13) 2021 Oct 14 Baang, Smith, Mirabelli (bib3) 2021 Jan 4; 223 Cattaneo, Cancelli, Imberti (bib7) 2021 Sep 14; 11 Kos, Balensiefer, Roth (bib6) 2020 Sep 2; 10 Tepasse, Hafezi, Lutz (bib8) 2020 Jul; 190 Karataş, İnkaya, Demiroğlu (bib4) 2020 Oct; 59 Wright, Bersabe, Eden (bib10) 2021 Jan; 21 Polack, Thomas, Kitchin (bib2) 2020 Dec 31; 383 Marcacci, Fiorentino, Volzone (bib9) 2021 Jun 2; 16 Marcacci (10.1016/j.jiac.2021.11.018_bib9) 2021; 16 Baang (10.1016/j.jiac.2021.11.018_bib3) 2021; 223 Wright (10.1016/j.jiac.2021.11.018_bib10) 2021; 21 Polack (10.1016/j.jiac.2021.11.018_bib2) 2020; 383 Marasco (10.1016/j.jiac.2021.11.018_bib13) 2021 Karataş (10.1016/j.jiac.2021.11.018_bib4) 2020; 59 Kos (10.1016/j.jiac.2021.11.018_bib6) 2020; 10 Kim (10.1016/j.jiac.2021.11.018_bib1) 2020; 24 Shah (10.1016/j.jiac.2021.11.018_bib5) 2020; 190 Passamonti (10.1016/j.jiac.2021.11.018_bib12) 2020; 7 Schwarzkopf (10.1016/j.jiac.2021.11.018_bib11) 2021; 27 Cattaneo (10.1016/j.jiac.2021.11.018_bib7) 2021; 11 Tepasse (10.1016/j.jiac.2021.11.018_bib8) 2020; 190 |
| References_xml | – volume: 11 start-page: 151 year: 2021 Sep 14 ident: bib7 article-title: Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab publication-title: Blood Cancer J – volume: 21 start-page: 66 year: 2021 Jan end-page: 68 ident: bib10 article-title: Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma publication-title: Clin Lymphoma, Myeloma & Leukemia – year: 2021 Oct 14 ident: bib13 article-title: T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies publication-title: Br J Haematol – volume: 10 start-page: 1578 year: 2020 Sep 2 ident: bib6 article-title: Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient After rituximab publication-title: Front Oncol – volume: 24 start-page: 11926 year: 2020 Nov end-page: 11933 ident: bib1 article-title: Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review publication-title: Eur Rev Med Pharmacol Sci – volume: 16 start-page: 38 year: 2021 Jun 2 ident: bib9 article-title: Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab publication-title: Infect Agents Cancer – volume: 7 start-page: e737 year: 2020 Oct end-page: e745 ident: bib12 article-title: Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study publication-title: Lancet Haematol – volume: 190 start-page: e279 year: 2020 Sep end-page: e282 ident: bib5 article-title: Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience publication-title: Br J Haematol – volume: 383 start-page: 2603 year: 2020 Dec 31 end-page: 2615 ident: bib2 article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine publication-title: N Engl J Med – volume: 59 start-page: 102871 year: 2020 Oct ident: bib4 article-title: Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma publication-title: Transfus Apher Sci – volume: 190 start-page: 185 year: 2020 Jul end-page: 188 ident: bib8 article-title: Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature publication-title: Br J Haematol – volume: 223 start-page: 23 year: 2021 Jan 4 end-page: 27 ident: bib3 article-title: Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient publication-title: J Infect Dis – volume: 27 year: 2021 Jan ident: bib11 article-title: Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG publication-title: Emerg Infect Dis – volume: 190 start-page: e279 issue: 5 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib5 article-title: Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience publication-title: Br J Haematol doi: 10.1111/bjh.16935 – year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib13 article-title: T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies publication-title: Br J Haematol – volume: 27 issue: 1 year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib11 article-title: Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG publication-title: Emerg Infect Dis doi: 10.3201/eid2701.203772 – volume: 10 start-page: 1578 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib6 article-title: Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient After rituximab publication-title: Front Oncol doi: 10.3389/fonc.2020.01578 – volume: 190 start-page: 185 issue: 2 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib8 article-title: Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature publication-title: Br J Haematol doi: 10.1111/bjh.16896 – volume: 11 start-page: 151 issue: 9 year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib7 article-title: Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab publication-title: Blood Cancer J doi: 10.1038/s41408-021-00546-9 – volume: 24 start-page: 11926 issue: 22 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib1 article-title: Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review publication-title: Eur Rev Med Pharmacol Sci – volume: 16 start-page: 38 issue: 1 year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib9 article-title: Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab publication-title: Infect Agents Cancer doi: 10.1186/s13027-021-00376-1 – volume: 21 start-page: 66 issue: 1 year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib10 article-title: Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma publication-title: Clin Lymphoma, Myeloma & Leukemia doi: 10.1016/j.clml.2020.06.012 – volume: 7 start-page: e737 issue: 10 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib12 article-title: Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study publication-title: Lancet Haematol doi: 10.1016/S2352-3026(20)30251-9 – volume: 223 start-page: 23 issue: 1 year: 2021 ident: 10.1016/j.jiac.2021.11.018_bib3 article-title: Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient publication-title: J Infect Dis doi: 10.1093/infdis/jiaa666 – volume: 383 start-page: 2603 issue: 27 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib2 article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 59 start-page: 102871 issue: 5 year: 2020 ident: 10.1016/j.jiac.2021.11.018_bib4 article-title: Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma publication-title: Transfus Apher Sci doi: 10.1016/j.transci.2020.102871 |
| SSID | ssj0017588 |
| Score | 2.3208795 |
| Snippet | Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 329 |
| SubjectTerms | Adult Antibodies, Viral Antibody Antibody Formation Case Report COVID-19 Humans Immunocompromised state Lymphoma Lymphoma, Mantle-Cell - drug therapy Male Rituximab Rituximab - therapeutic use SARS-CoV-2 |
| Title | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X21003299 https://dx.doi.org/10.1016/j.jiac.2021.11.018 https://www.ncbi.nlm.nih.gov/pubmed/34887178 https://www.proquest.com/docview/2608537168 https://pubmed.ncbi.nlm.nih.gov/PMC8612813 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqcuGCeFMolZFQL9TddcZ57HG1UG1BlIptq71FduyIVN1ktc1KzYU_wp9lJq-ygIqElEPijCMrM5mHM_MNY28BVAgARqQYLAsldSQ0tQyzgSeDkY-jAdU7fz4Jpufq49yfb7FJVwtDaZWt7m90eq2t25FB-zYHyywbzAiKDDw5x6BlCKhVqYJdhSTlh9_7NA-0jnXvSSIWRN0WzjQ5XpeZJhhDTx4Skic1_vi7cfrT-fw9h_IXo3T0kD1ovUk-bhb8iG25_DHbP23gqKsDfnZbXXV9wPf56S1QdfWE_aDYE0W54lRkwnEZbuX4knbQkPd5ySdfLo7fCznitFtbrEvu2h6kvEi5zvEoMzEbf52JSXEhvPraFLbiqybz1vEMifgCSekJdIKiyelnAb-qUI6KheZ1qruzDcUqK9c32UKbp-z86MPZZCraZg0i8WFYIoet87UNfDc0NgFpXZikEQQmAAtWp5AqT2nAMXSxHNpL6bRJEwyQ01BjEAvP2HZe5O4F49pGdpQoZYZKK-O5CKwNDaoKHaVSOthhsuNSnLRI5tRQ4yruUtYuY-JsTJzFECdGzu6wd_2cZYPjcSc1dMyPuwpV1Kkxmpk7Z_n9rA0Z_ue8N518xfhxExN07or1dYzBJrpTGNIizfNG3vrVA6pejMXxTrghiT0BAYdv3smzbzWAeBTQ_1N4-Z_rfcXue1QEUueu77LtcrV2r9E1K81e_e3tsXvj40_Tk5_2PDt3 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V5QAXxJvyXCTohbrJetePHDhUKVVCH1QkrXLb7nrXwlVjR4kj8IU_ws_gDzLjVwmgIiFVyiFZz0Yjz8y3M_Y8CHnNuQg459qJIVh2BFOho3BkmPFd5vc8WPWx3vnwyB-ciA8Tb7JGfjS1MJhWWWN_heklWtcrnfpudmZJ0hlhKzLusgkELV0OqFpnVu7b4gvEbYt3w10Q8hvX3Xs_7g-cerSAE3m8mwM_xnrK-J7tahNxZmwQxSH3tc8NNyrmsXCF4rAGDoEFdGdW6TiCcC4OlCi7HQDu3xAAFzg2Yftbm1cCx3E57BK5c5C9ulKnSio7TxT2TXTZNrYOxUkjfz8N__R2f0_a_OUU3LtDbtfuK92p7tBdsmbTe2TzuOp_XWzR8WU512KLbtLjy87YxX3yHYNdsJ2CYlULBTbs3NIZPrIDZUtz2v94Otx1WI_i4-FsmVNbDz2lWUxVCp88cUY7n0ZOPzt13PK3zkxB51Wqr6UJENEpkOI_4BewBYpvJ-hFAYqbTRUtc-utqSjmSb78mkyVfkBOrkWED8l6mqX2MaHKhKYXCaG7Qgnt2pAbE2jAJhXGjFm-QVgjJRnVrdNxgseFbHLkziVKVqJkIaaSINkN8rbdM6sah1xJzRvhy6YkFkBcwrl25S6v3bViNP_c96rRLwlogkJQqc2WCwnRLfhvEEMDzaNK31ruOWA9BP9wJVjRxJYAO5WvXkmTz2XH8tDHF7b8yX_y-5LcHIwPD-TB8Gj_KbnlYgVKmTj_jKzn86V9Dn5hrl-UdkjJ2XUb_k-eynjV |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recovery+from+severe+persistent+COVID-19+without+evidence+of+an+anti-SARS-CoV-2+antibody+response+in+a+man+with+mantle+cell+lymphoma+treated+with+rituximab&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Horiuchi%2C+Hiroshi&rft.au=Sasaki%2C+Hiroaki&rft.au=Miyazaki%2C+Kazuhito&rft.au=Miyata%2C+Nobuyuki&rft.date=2022-02-01&rft.pub=Elsevier+Ltd&rft.issn=1341-321X&rft.volume=28&rft.issue=2&rft.spage=329&rft.epage=332&rft_id=info:doi/10.1016%2Fj.jiac.2021.11.018&rft.externalDocID=S1341321X21003299 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon |